RHINOCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHINOCORT (RHINOCORT).
Corticosteroid that inhibits inflammatory mediators (e.g., prostaglandins, leukotrienes) and reduces nasal mucosa inflammation.
| Metabolism | Hepatic via CYP3A4; undergoes first-pass metabolism. |
| Excretion | Budesonide (active ingredient) is primarily eliminated via hepatic metabolism (CYP3A4) with metabolites excreted in urine (60%) and feces (40%). Unchanged drug in urine is less than 10%. |
| Half-life | Terminal elimination half-life is 2.0–3.6 hours in adults, allowing twice-daily dosing. |
| Protein binding | 85–90% bound to albumin. |
| Volume of Distribution | 2.2–3.9 L/kg; extensive tissue distribution. |
| Bioavailability | Intranasal: ~34% (due to first-pass metabolism). Oral inhalation: ~11%. Oral: <1%. |
| Onset of Action | Intranasal: 3–7 hours for first dose; peak effect may take 1–2 weeks. |
| Duration of Action | Intranasal: ~12 hours; clinical improvement sustained with regular use. |
2 sprays (64 mcg) per nostril once daily, or 1 spray (32 mcg) per nostril twice daily; intranasal use.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Children 6-12 years: 1 spray (32 mcg) per nostril once daily; some guidelines allow up to 2 sprays per nostril once daily if needed. Children ≥12 years: same as adult. |
| Geriatric use | No specific adjustment; initiate at lower end of dosing range due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RHINOCORT (RHINOCORT).
| Breastfeeding | It is unknown whether budesonide is excreted in human breast milk after intranasal administration; however, other corticosteroids are excreted in small amounts. Because plasma concentrations after intranasal dosing are very low, the amount in breast milk is expected to be minimal. The milk-to-plasma ratio is not available for intranasal budesonide; for oral/inhaled forms, M/P ratio ~0.4. Use with caution in nursing mothers, weighing potential risks against benefits. |
| Teratogenic Risk | Budesonide (Rhinocort) is classified as Pregnancy Category B. No teratogenic effects have been observed in animal studies at doses up to 100 times the maximum human intranasal dose. In human studies, inhaled budesonide during pregnancy showed no increased risk of congenital malformations. However, intranasal administration results in negligible systemic absorption, minimizing fetal exposure. Nonetheless, use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","Untreated nasal mucosal infections"]
| Precautions | ["Nasal septal perforation","Impaired wound healing","Increased intraocular pressure/glaucoma","Cataracts","Adrenal suppression with high doses","Growth retardation in children"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. However, monitor for systemic corticosteroid effects if used long-term or at high doses, including adrenal suppression, growth retardation in fetus, and maternal hyperglycemia. Nasal examination periodically for mucosal changes. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data with intranasal budesonide. Systemic corticosteroids may impair fertility, but intranasal route yields negligible systemic exposure. |